Biohaven Ltd. (BHVN): Cash & Equivalents
$229.96M
As of 2025-12-31
$238.03M
As of 2026-06-30
+3.9%
3-year compound annual growth
+22.8%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $229.96M | +132.0% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $99.13M | -60.1% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $248.40M | +21.2% | 2026-03-02, Balance as of period end |
| 2022-12-31 | $204.88M | +169.4% | 2025-03-03, Balance as of period end |
| 2021-12-31 | $76.06M | -7.8% | 2024-02-29, Balance as of period end |
| 2020-12-31 | $82.51M | n/a | 2023-03-23, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Biohaven Ltd. (BHVN) | 2025-12-31 | $229.96M | +132.0% |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | 2025-12-31 | $373.69M | n/m |
| BGM Group Ltd. (BGM) | 2025-09-30 | $9.82M | 0.0% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $42.91M | -39.9% |
| Bicara Therapeutics Inc. (BCAX) | 2025-12-31 | $96.69M | -80.3% |
| Enliven Therapeutics, Inc. (ELVN) | 2025-12-31 | $98.90M | -20.3% |
| MapLight Therapeutics, Inc. (MPLT) | 2025-12-31 | $46.73M | +22.2% |
| MoonLake Immunotherapeutics (MLTX) | 2025-12-31 | $334.52M | +85.4% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $54.30M | -39.1% |
Compare BHVN, BBOT, BGM, ARQT side by side · Screen every company in Pharmaceutical Preparations ↗